Testosterone replacement: when is there a role?
|
|
- Brett Poole
- 5 years ago
- Views:
Transcription
1 (2000) 12, Suppl 4, S112±S118 ß 2000 Macmillan Publishers Ltd All rights reserved /00 $ Testosterone replacement: when is there a role? 1 * 1 Queens University, Department of Urology, Kingston General Hospital, Kingston, Canada Hypogonadism is an uncommon cause of erectile dysfunction. Unfortunately, hypogonadal states in adult males are dif cult to diagnose on purely clinical grounds and it is necessary to seek biochemical support. The simplest way to establish the diagnosis of hypogonadism is by determination of serum testosterone levels. Several methods exist but total testosterone determination plus assessment of sex hormone-binding globulin or bio-available testosterone appear to be the most reliable and accessible. Once a diagnostic of hypogonadism has been established in a man with erectile dif culties, a trial of androgen supplementation is warranted if no contraindications exist. Knowledgeable monitoring is essential. In the absence of an adequate response, co-morbidities should be diligently sought out. In the absence of reliable guidelines for androgen administration to patients with erectile failure, a set of recommendations are provided. (2000) 12, Suppl 4, S112±S118. Keywords: erectile dysfunction; pharmacotherapy; androgens; review Introduction The aging process in men is associated with variable but sometimes profound hormonal alterations and a decrease in sexual performance. 1 This should not be construed to imply that the latter is exclusively a consequence of the endocrine changes. The Massachusetts Male Aging Study (MMAS) was unable to associate the coexistence of ED and changes in the serum levels of sex hormones with the notable exception of a direct correlation between sexual dysfunction and a serum de cit in dehydroepiandrosterone (DHEA) and its sulfated form (DHEAS). This nding is dif cult to interpret because, although hypotestosteronemia and aging show a very marked inter-individual variability, the association of low DHEA and advancing age exhibits a more predictable, constant and profound association. In other words, ED and the decease in serum levels of DHEA is so prevalent in the elderly that their relationship may simply be coincidental, and not necessarily related. It is widely accepted that androgens are important for general sexual function and the role of androgens in erectile physiology is particularly fundamental. Current estimates indicate that 1 in 200 male adults have abnormally low levels of testosterone (T) and most of these men are candidates for androgen supplementation therapy. 2 *Correspondence:, Queens University, Department of Urology, Kingston General Hospital, Kingston, ON K7L 2V7 Canada. Moralesa@post.queensu.ca Testosterone and sexual function Although it is possible to obtain erections and maintain some semblance of libido with minimal levels of androgens, in general castrate levels of T result in suppression of both sexual interest and performance. 3 Nevertheless, the prevalence of hypogonadism in men with ED is low 4 and its presence may not re ect causality. Solid evidence has shown that profound hypogonadism results in the early abolition of erections associated with rapid eye movement (REM) sleep while erotically stimulated erectile function may be preserved during wakefulness. 5 In addition to having a detrimental effect on erectile activity, hypogonadism brings a diminution in the frequency of sexual thoughts and intercourse. Its adverse effect on the volume of the ejaculate and semen quality are also well recognized. 6 Should men with ED be investigated for hypogonadism? A great deal of controversy has existed in the literature regarding this issue. Those opposing the routine hormonal assessment argue that hypogonadism is a rare cause of ED, the cost of the testing is considerable and, above all, it can be suspected by its effect on libido. Let us examine these points individually. The prevalence of hypogonadism in the age group with the highest incidence of ED (middle age and
2 beyond) is higher than initially suspected. 7 Morley et al 8 reported a signi cant incidence of androgen de ciency in males, as measured by serum levels of bioavailable T. Nevertheless, it is recognized that hypogonadism is rarely the main etiological factor in ED, a view further supported by the limited success of adequate exogenous T supplementation in the treatment of ED. 9,10 The cost of determining serum T is dif cult to assess and depends on a number of variables. These variables include: the degree of laboratory sophistication, the type of T determination (total, free or bioavailable), the number of tests requested and the type and number of supplementary tests ordered (determination of sex hormone-binding globulin, gonadotropins) to facilitate accurate interpretation of the results. The basic determination of total serum T is inexpensive (under $10.00). The view that the diagnosis of hypogonadism can be established on the basis of history and physical examination is a fallacy. Adult hypogonadism, except in the most extreme cases, is dif cult to diagnose accurately without biochemical investigations. 11 Thus, sexual interest is a notoriously unreliable symptom that may be prominent in men with normal T levels but affected by other conditions (eg depression 12 ). Testicular size and consistency in the adult male show marked inter-individual variability and the appearance of secondary sex characteristics are not suf cient to suspect or rule out the presence of hypoandrosteronemia. 13 The clinician is, therefore, obliged to seek biochemical assistance before embarking upon treatment of ED. It should be noted, however, that the diagnosis of a medically signi cant hypogonadism should be based on a comprehensive evaluation of the patient and his biochemical test results. Finally, the author's opinion is that it is clinically parochial and inappropriate to consider hypogonadism only from a purely sexual perspective. After all, as noted above, men seeking professional help for ED belong to an age group in which there is clear and signi cant increase in the prevalence of deterioration in the function of the hypothalamic-pituitary-gonadal axis. 1,6,9,12 Unquestionably, it is the responsibility of the clinician (in general) and the urologist (speci cally) to rule out the presence of a hypogonadal state with its subtle but dire consequences beyond sexual problems (ie, depression, osteoporosis, detrimental alterations in lipid pro le, etc). 14 The minimal hormonal evaluation Measuring total serum T levels, preferably in the morning between 8 and 10 am can determine the androgenic milieu. This is the simplest, least expensive and readily accessible test method to rule out an abnormality in serum T. However, the results may be misleading, particularly in obese and in elderly men because this subset of patients commonly exhibit increased levels of sex-hormone binding globulin (SHBG), which prevents T from becoming metabolically active. Free T levels may provide a better estimation of testicular endocrine function but the fastidiousness required in the technique results in inter- and intra-laboratory variability, casting reservations on the accuracy of the test. Measuring bioavailable T (the sum of free albumin-bound T) may be the most reliable measurement because it determines the amount of T which is available to target tissues. Unfortunately, determinations of bioavailable T are not widely performed and are more costly. An appropriate compromise that takes into consideration the accuracy of test results, cost and availability is the simultaneous determination of total T and SHBG by immunoassay. 15 Regardless of the test employed, if an abnormal value is obtained with the initial determination, the results should be con rmed with a second test, particularly when the abnormality is borderline. If the abnormality is con rmed, it may then be appropriate to further investigate the hypothalamus ± pituitary ± gonadal axis by measuring levels of gonadotropins (FSH and LH). The measurement of prolactin may also be appropriate in this case, since hyperprolactinemia is frequently seen in the presence of hypotestosteronemia. As opposed to the clinical manifestations of low T levels (where libido is a poor clinical marker), this author has not yet observed a patient with a functional prolactinoma who did not also present with a marked decrease in sexual desire. Other hormones Further hormonal evaluation depends on the interest, expertise and commitment of the physician and, obviously, the patient's clinical picture. Despite overwhelming evidence to support its existence, androgen decline in the aging male (ADAM) also known as the andropause, continues to be debated. Part of the controversy is based on the vagaries and inconsistencies of the syndrome 16 and production of several other hormones are frequently affected during the aging process. For instance, diminution in muscle mass and strength have long been recognized as a sequelae of hypogonadism, 17 more recently, similar alterations were documented in adults with growth hormone de ciency. Disturbances in sleep patterns may equally be attributed to low levels of T or melatonin. These close interactions between endocrine systems and their target organs are poorly understood but our limitations in knowledge should not justify the denial of their existence. The alterations in the hormonal milieu occurring with age are incontrovertible. Basic biochemical endocrine evaluation in a man complaining of ED should include serum T. Initially, a more comprehensive assessment may not be justi ed, but further S113
3 S114 assessment is clearly indicated if hypogonadism is documented. For instance, the measurement of pituitary gonadotropins, follicle stimulating hormone (FSH) and luteinizing hormone (LH) can provide an indication whether primary, secondary or tertiary hypogonadism is the cause. However, it must be remembered that at middle age and beyond, there is a diminution in pituitary function that results in a attening in the circadian production of gonadotropins. 18 Therefore, it is not uncommon to encounter men with erectile problems (who are most commonly in these age groups) and primarily testicular failure resulting from a breakdown of the feedback mechanisms, ie, a low serum T with normal or only minimally elevated gonadotropins. Measurement of other endocrinological parameters (ie DHEA, growth hormone, melatonin, and leptin) is not indicated in the context of erectile dysfunction, but thyroid function may have an impact on sexual performance. Such an occurrence is exceedingly rare and the routine assessment of thyroid function is unlikely to be productive. However, hyprothyroidism may result in hyperprolactinemia, therefore, assessment of thyroid function in hyperprolactenemic patients is indicated. 19 On the other hand, levels of total testosterone may appear abnormally high in the presence of normal bioavailable T in patients with hyperthyroidism. 20 Justi cation for androgen supplementation In the context of ED, exogenous androgens are indicated if hypogonadism is documented with or without alteration in sexual desire. Libido is a poor indicator of androgenic homeostasis unless there is a profound hypotestosteronemia. Low serum T levels may co-exist with a variety of other important conditions which are well recognized causes of erectile failure (atherosclerosis, diabetes and a variety of erectolytic medications 21 ). However, in the presence of hypogonadism and ED it is justi ed to consider a trial of exogenous androgen therapy. The reasons for this view include the simplicity and safety of the treatment and the presence of a documented etiology. The response, in terms of recovery of erectile function and improvement in sexual interest, is not spectacular. Our experience and that of others clearly indicates that only a limited number of men undergo restoration of erections and improvement in libido secondary to androgen supplementation. 9,10,21 Patients not responding to T administration require reevaluation to rule out associated causes. A trial of androgen administration should be not shorter than 3 months. At the end of this period a re-assessment of sexual function and other parameters is indicated. Continuation of T administration would then depend on the clinical response and possible alter-ations in other organ systems resulting from treatment. It is evident that androgen supplementation for conditions such as osteoporosis requires a prolonged course of no less than several years before an objective improvement can be documented. 22 Treatment options Androgens can be administered by several routes, each one offering a different set of advantages and drawbacks. 23 Parenteral Injectable esters of T have been available for the longest period of time and their effects are well recognized. 24 They are inexpensive and safe but their use carries several major drawbacks which include: (a) the need for periodic (every 2 ± 3 weeks) deep intramuscular injection; (b) the administration of injectable preparations results, in the rst 72 hours, in supraphysiological levels of serum T followed by a steady decline over the next 10 ± 14 days; 25 (c) the steady decline in T levels frequently results in a very low nadir immediately before the next injection. This phenomenon translates into wide swings in mood and well being (the roller-coaster effect) which is disconcerting and upsetting to both patients and their partners; (d) parental androgens do not provide the normal circadian patterns of serum testosterone and the intermittent supra-physiological levels they produce may result in the development of breast tenderness and gynecomastia. The most widely used parenteral preparations are the 17-b-hydroxyl esters of testosterone which include the short acting propionate and the longer acting enanthate and cypionate. Currently, the propionate is rarely used because its short half-life requires that it be administered every other day. The enanthate and cypionate, on the other hand, can be administered in doses between 200 mg and 400 mg every 10 ± 21 d to maintain normal average testosterone levels. 26 Higher doses will not maintain T levels in the normal range beyond the 3-week limit. Appropriate treatment of hypogonadism with injectable esters of T has been shown to improve libido, sexual function, energy levels, mood and bone density if the symptoms are caused by an androgen de ciency. 18 Persistent supraphysiologic levels of serum T may result in infertility due to suppression of LH and FSH production. 27 Although concern exists about the psychosexual effects of markedly elevated levels serum T, published evidence indicates that, even in eugonadal men,
4 amounts up to ve times the normal physiological replacement doses of T cypionate have only minimal psychosexual effects. 28,29 result in various degrees of dermatitis, occasionally producing signi cant chemical burns. S115 Oral preparations These demand special consideration because they undergo rapid hepatic metabolism and may, therefore, fail to result in adequate serum levels of androgens. In order to prevent metabolism by the liver, oral agents available in the USA are alkylated preparations. However, these alkylated preparations generally provide erratic androgenic activity and exhibit a potential for signi cant liver toxicity which has included: hepatocellular adenomas, cholestatic jaundice and hemorrhagic liver cysts. 30 Testosterone undecanoate is yet another oral preparation that is not, at present, available in the USA but it is widely used throughout the world. As the only effective oral testosterone ester, when taken with meals it circumvents the rst passage through the liver. It is free of liver toxicity and brings serum T levels within physiological range. It is liposoluble and for this reason it must be taken with meals. None of the oral medications cited above results in a faithful re ection of the circadian level variations. However, careful selection of the timing and amount of the dosing may ameliorate this problem. Transdermal T therapy Transdermal T therapy (TTT) results in serum T levels within the range observed in normal men over the 24 h circadian cycle. TTT is available in both scrotal and non-scrotal patches. The former has lost appeal due to inconveniences such as its ability to remain in place and the need for frequent shaving of the scrotal skin. In addition, due to the high concentrations of 5-alpha reductase in the scrotal skin, abnormally high serum levels of dihydrotestosterone (DHT) have been reported. 31 Either patch applied at bedtime will result in peak T levels in the early morning and a nadir just prior to their replacement. Transdermal non-scrotal patches also produce normal levels of estradiol, but, unlike the scrotal patches, these do not result in abnormal levels of DHT. 31 In addition to producing physiologically appropriate serum levels of T, they actually lower the level of sex hormone binding globulin (SHBG), promote virilization and increase bone mineral density. 32 Finally, the T patches, compared to injectable forms of T, minimize excessive eryth-ropoiesis and suppression of gonadotropins. 33 The most common side effects of the non-scrotal transdermal patches are related to the enhancers used to facilitate absorption; these enhancers frequently Other preparations Delivery forms not widely prescribed but worth mentioning include long acting implantable subcutaneous pellets and microcapsules. 34,35 The subcutaneous implants are not associated with high DHT levels, which is desirable when treating older hypogonadal man in whom concerns regarding the prostate gland are of paramount importance. The signi cance of elevated levels of DHT, which are more common with oral or scrotal administration of T still remains to be clari ed. Similarly, MENT (7a-methyl-19 nortestosterone), which is not reduced to DHT but aromatized to estradiol, would be more desirable in the presence of urinary obstructive symptoms. New frontiers in androgen therapy It is recognized that androgen receptors (AR) are widely distributed among reproductive and nonreproductive tissues in the body. Of interest in the treatment of sexual dysfunction is their ubiquitous presence in the pineal gland and brain cortical and subcortical regions and male external genitalia. This wide distribution permits envisioning the hypothetical exploitation of selective androgen receptor modulators (SARMS) 36 with a speci c activity in the target tissue of interest. Since SARMs are not substrates for 5a-reductase activity, 35 it would be possible to achieve adequate levels of androgens in the brain and genitalia without a concomitant increase in the prostate or seminal vesicles. The development of such molecules is currently becoming a reality. 37 Responsibility with treatment Male hypogonadism, as mentioned before, affects a variety of organs and the limited view of its exclusive importance in sexual function is too con ning and may be detrimental to patient care. However, for the purposes of this review, it can be categorically established that low T levels in a man with sexual dysfunction are a clear indication for hormone replacement therapy (HRT). If there are no correctable causes attributable to the endocrine dysfunction, a limited period of hormonal treatment (ie, 3 ± 6 months) is usually suf cient to establish a cause ± symptom relationship. Obviously, if adequate HRT does not result in an appropriate response, a search for other co-morbidities becomes mandatory.
5 S116 Other sequelae of hypogonadism may coexist with ED; in this situation, prolonged T administration is indicated even if the sexual problems fail to show improvement. There is a persistent and somewhat justi ed concern about undesirable side effects that may result when some of the currently available androgen preparations are prescribed ethically or when abused by athletes and body builders. The potential for adverse effects is of particular concern in the liver, the prostate, lipid pro le and cardiovascular system, sleep patterns and social behavior and emotional state. These considerations have been reviewed recently. 16 Recommendations The current state of knowledge within the narrow con nes of androgen therapy in men with ED permits the development of a set of recommendations (not yet guidelines) which appear appropriate until a pertinent scienti c society or regulatory agency develops guidelines or standards with universal credibility and appeal. They are as follows: (1) The diagnosis of adult hypogonadism based on a history of low sexual desire is notoriously unreliable. The physical examination is also unreliable except in the most profound cases. Biochemical determinations are, therefore, recommended to establish a rm diagnosis. Either a total T and SHBG or bioavailable T are the most dependable tests. (2) Due to the pulsatile nature of T production, it is prudent to con rm an abnormal result. (3) T administration must be supported by a clear indication (clinical judgement and biochemical information). (4) Borderline levels of serum T may be of limited relevance and may not correlate well with sexual desire and performance. Such cases demand careful consideration of the advantages and drawbacks of androgen therapy. Nevertheless, a limited therapeutic trial is usually warranted. (5) In a man with concomitant hypogonadism and ED, a 3 ± 6 month period of hormonal supplementation is indicated. Failure to respond to therapy despite reaching eugonadal serum T levels is an indication to search diligently for co-morbidity. In the absence of a response and if no other sequelae of hypotestosteronemia exist, discontinuation of treatment should be considered. (6) Men with secondary hypogonadism (of hypothalamic-pituitary origin) may experience bene t by treatment with gonadotropins or clomiphene. 38 (7) Although not yet proven, in hypogonadal men, co-administration of T with an erectogenic drug may show synergistic or supra-additive ef cacy. 39 (8) In men over the age of 40 y a digital rectal examination (DRE) and prostatic speci c antigen (PSA) determination are mandatory. Biopsy of the prostate is reserved for those in whom an abnormality is detected. (9) The suspicion or presence of cancer of the prostate or breast are absolute contraindications for androgen therapy. (10) The T preparation, dose and route of administration need to be selected carefully depending on the individual needs and circumstances of the patient. (11) For the rst year after the onset of therapy, patients should be followed quarterly to assess response to therapy (clinical and biochemical) including hemoglobin, DRE and PSA. Patients who remain stable may subsequently be followed annually, at which time other tests of liver function and lipid pro le should be included. (12) During therapy serum T levels may uctuate considerably, particularly with the use of the intramuscular preparations. In the speci c situation of the hypogonadal impotent man, the clinical response is the most reliable guide to dose requirements. Conclusions Hypogonadism is not a common cause of ED. However, its clinical diagnosis in the adult is dif cult and normally requires biochemical investigations. A serum T determination is justi ed in men complaining of ED with or without alterations in sexual desire. The prevalence of ED is particularly common at a point in life when alterations occur in men's hormonal environment. Even though ED may not be a consequence of the changing hormonal mileu, the consequences of hypogonadism in other organ systems are increasingly recognized and timely diagnosis and appropriate treatment may signi cantly improve the patient's quality of life. References 1 Feldman HA et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54 ± Replacing testosterone in men. Drug Ther Bull 1999; 37: 3 ± 6. 3 Bancroft J, Wu, CFW. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav. 1983; 12: 59.
6 4 Nickel JC et al. Endocrine dysfunction in impotence. Incidence, signi cance and cost-effective screening. J Urol 1984; 130: 40 ± Nieschlag E, Behere HM. Pharmacological and clinical uses of testosterone. In: Nieschlar A, Behere, HM, (eds). Testosterone: action, de ciency, substitution. Springer-Verlag: Berlin, 1998, pp 294 ± Burris AS et al. A long-term prospective study of the physiologic and behavioural effects of hormone replacement in untreated hypogonadal men. J Androl 1992; 13: 297 ± Vermeulen A. Androgens in the aging male. J Clin Endocrinol Metab 1991; 73: 221 ± Morley JE. Clinical diagnosis of age-related testosterone de ciency. Aging Male 2000; 3(Suppl. 1): Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav. 1983; 12: 59 ± Morales A, Johnston B, Heaton JPW, Lundi M. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measurements and therapeutic outcomes. J Urol 1997; 157: 849 ± Ansong KS, Punwaney RB. An assessment of clinical relevance of testosterone level determination in the evaluation of men with low sexual drive. J Urol 1999; 162: 719 ± Christiansen K. Behavioural correlates of testosterone. In: Nieschlan E, Behere HE, (eds). Testosterone: Action, De ciency, Substitution. Springer-Verlag: Berlin, 1998, pp 107 ± Montague DK. Editorial: medical therapies for erectile dysfunction. J Urol 1999; 162: Mauras N et al. Profound hypogonadism has signi cant negative effects on calcium balance in males: a calcium kinetic study. J Bone Miner Res 1999; 14: 577 ± Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666 ± Morales A, Heaton JWP, Carson CC III. Andropause: a misnomer for a true clinical entity. J Urol 2000; 163: Bhasin S, Tenover JS. Sarcopenia: issues in testosterone replacement of older men. J Clin Endocrinol Metab 1997; 82: 1659 ± Russell-Aulet M, Jaffe CA, Demott-Frieberg R, Barkan AL. In vivo semiquanti cation of hypothalamic growth hormonereleasing hormone (GHRH) output in humans: evidence for relative GHRH de ciency in aging. J Clin Endocrinol Metab 1999; 84: Grubb MR, Checkers D, Malarkey WB. Patients with primary hypothyroidism presenting as prolactinomas. Am J Med 1987; 83: Vermeulen A, Stoica T, Verdonck L. The apparent free testosterone concentration and index of androgenicity. J Clin Endocrinol Metab 1971; 3: 759 ± Morales A, Heaton JPW, Johnston B, Adams M. Oral and topical treatment of erectile dysfunction: present and future. Urol Clin NA 1995; 22: 879 ± Guo C-Y, Jones TH, Eastell R. Treatment of isolated hypogonadotropic hypogonadism. Effect on bone mineral density and turnover. J Clin Endocrinol Metab 1997; 82: 658 ± Morales A, Baines J, Ruijs A, Tremblay RR. Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. Int J Impot Res 1996; 8: Thompson, WO. Uses and abuses of the male sex hormone. JAMA 1946; 132: 185 ± Sokol RZ, Palacios A, Camp eld LA. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 1982; 37: 425 ± Bhasin S. Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992; 74: 1221 ± Bhasin S, Bremner WJ. Emerging issues in androgen replacement therapy. J Clin Endocrinol. Metab 1997; 82: 3 ± Yates WR et al. Psychosexual effects of 3 doses of testosterone cycling in normal men. Biol Psychiat 1999; 45: 254 ± Bagatell CJ, Bremner WJ. Drug therapy: androgens in men ± uses and abuses. New Engl J Med 1996; 334: 707 ± Bradwin SW, Swerdloff RS, Santen RJ. Androgens: risks and bene ts. J Clin Endocrinol Metab 1991; 73: 4±7. 31 Arver S, Meikle AW, Dobbs AS, Maze NA. Permeation enhanced testosterone transdermal systems in the treatment of male hypogonadism: long term effects. J Endocrinol 1996; 148: 254 ± De Sanctis V et al. Clinical experience using Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major. J Ped Endocrinol Metab 1999; 11(Suppl 3): 891 ± Dobbs AS et al. Pharmacokinetics, ef cacy and safety of permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84: 3469 ± Handelsman DJ et al. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrin 1997; 47: 311 ± Hasin S, Swerdlof RS, Steiner B. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10 ± 11 weeks in hypogonadal men. J Clin Endocrinol Metab 1992; 74: 75 ± Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrin Metab 1999; 84: 3459 ± Moilanen AM et al. A testis-speci c androgen receptor coregulator that belongs to a novel family of nuclear proteins. J Biol Chem 1999; 274: 3700 ± Guay AT, Bansal S, Hodge MB. Possible hypothalamic impotence. Male counterpart to hypothalamic amenorrhea? Urology 1991; 38: 317 ± Heaton JPW, Adams MA, Morales A. A therapeutic taxonomy of treatments for erectile dysfunction: en evolutionary imperative. Int J Impot Res 1997; 9: 115 ± 119. S117
7 S118 Appendix example, polycythemias, and some people develop sleep apnea on testosterone replacement. Open discussion following Dr Morales' presentation Dr Pryor: In evaluating testosterone levels, we need to remember that it's a biorhythm that peaks in the morning and troughs in the afternoon. If you get a borderline or low level in a patient whose appointment is in the afternoon, you should repeat the test in the morning. Dr Morales: Yes. In fact, in older impotent men and in obese men, there is also a attening of the cycle. Testosterone may be normal, but these people have very high levels of sex hormone binding globulin. Always take measurements between 8:00 and 11:00 am. In the afternoon the levels are going to be lower. Dr Pryor: Another point I'd like to make is about the side effects that some are not as familiar with, for Dr Eid: Is there such a thing as a low testosterone level? Is it abnormal or normal? The concept of low testosterone, is that real or is that something we've made up? Dr Morales: I think it's real. Dr Lisa Tanover says that, in America if your testosterone is less than 250, that's de nitely abnormal; no question about it. You have to use clinical judgement. Given three months of testosterone, if the patient doesn't improve, you should look for comorbidity. One thing we have to eliminate is the urologists' parochial view that testosterone is sex. Testosterone has many other functions. I believe it's a central conditioner. I have a patient with a testosterone level of one, and cancer of the prostate. Two months ago I put a penile prosthesis in him and his libido is pretty good. But, because we don't understand many of these things, I don't think that's an argument for not treating these patients.
6/14/2010. GnRH=Gonadotropin-Releasing Hormone.
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
More informationHypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationManaging Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
More informationSevere erectile dysfunction is a marker for hyperprolactinemia
(2001) 13, 176±182 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Severe erectile dysfunction is a marker for hyperprolactinemia AM Johri 1, JPW Heaton 1 * and
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationLate onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationTestosterone Therapy in Men with Hypogonadism
Testosterone Therapy in Men with Hypogonadism (Endocrine Society 2018 Guideline) Ngwe Yin, MD Assistant Clinical Professor of Medicine, UCSF Fresno Medical Education Program Disclosures None Objective
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by
More informationGUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationTestosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
More informationTestosterone Injection / Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Testosterone Injection / Implant Page: 1 of 9 Last Review Date: December 5, 2014 Testosterone
More informationA dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
More informationSexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
More informationANDROGEN DEFICIENCY/MALE HYPOGONADISM
Medical Information to Support the Decisions of TUE Committees 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of
More informationEvaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
More informationANDROGEN DEFICIENCY/MALE HYPOGONADISM
ANDROGEN DEFICIENCY/MALE HYPOGONADISM 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (androgen deficiency)
More informationLow Testosterone Consultation Information
T Low Testosterone Consultation Information www.urologyaustin.com Andropause or Male Menopause This syndrome has been nicknamed ADAM, which stands for androgen deficiency of the aging male. It differs
More informationTESTOSTERONE DEFINITION
DEFINITION A hormone that is a hydroxyl steroid ketone (C19H28O2) produced especially by the testes or made synthetically and that is responsible for inducing and maintaining male secondary sex characteristics.
More informationHypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More informationHow to treat: TRT modalities and formulations
How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement
More informationHormone Replacement Therapy For Men Consultation Information
Hormone Replacement Therapy For Men Consultation Information www.urologyaustin.com Biological Aging and Hormones As we age, a natural degeneration and aging of organs causes the levels of our hormones
More informationRecognizing and Managing Testosterone Deficiency
Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: December 8, 2017 Testosterone
More informationOver the past decade, androgen replacement
J. Andrew Hoover, MD; Jeffrey T. Kirchner, DO, FAAFP Department of Family and Community Medicine, Lancaster General Hospital, Pa jhoover4@lghealth.org The authors reported no potential conflict of interest
More informationBIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationANDROGEN DEFICIENCY Update on Evaluation and Management
ANDROGEN DEFICIENCY Update on Evaluation and Management Kristen Gill Hairston, MD, MPH Associate Professor of Internal Medicine Section of Endocrinology and Metabolism Wake Forest University School of
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone
More informationAndrogen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital
Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen
More informationHYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Hypogonadism: Treatment Safety and Prostate Health 2 Monitoring for Testosterone Therapy DRE 1,2 PSA Parameter Voiding/IPSS 1,2 Hemoglobin
More informationISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN
International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency
More informationInvestigation, treatment and monitoring of late-onset hypogonadism in males
The Aging Male 2002;5:74 86 86 Standards, Guidelines and Recommendations of The International Society for The Study of the Aging Male (ISSAM) Investigation, treatment and monitoring of late-onset hypogonadism
More informationMale New Patient Package
Male New Patient Package The contents of this package are your first step to restore your vitality. Please take time to read this carefully and answer all the questions as completely as possible. Thank
More informationPCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS
Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal
More informationTUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees MALE HYPOGONADISM MALE HYPOGONADISM
1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (testosterone deficiency) and in some instances normal
More informationPRISM Bruges June Herman Leliefeld Urologist. The Netherlands
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone Oral Buccal Nasal Description
More informationHow Long Does It Take For Testosterone Replacement Therapy to Work?
How Long Does It Take For Testosterone Replacement Therapy to Work? When will I feel the effects? Dr Kevin J Meuret How Long Does it Take For Low Testosterone Treatment To Work? Great Question. New clients
More informationImplantable Hormone Pellets
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationImplantable Hormone Pellets
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationA USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW
A USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW 1. Why men need to know more Good health is vital for a happy and full life. But, with work and family responsibilities, men often overlook their own health
More informationClinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:
Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone Oral Buccal Nasal
More informationDiagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes
Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine
More informationTestosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
SPECIAL FEATURE Clinical Practice Guideline Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline Shalender Bhasin, Glenn R. Cunningham, Frances
More informationOVERVIEW OF PRESENTATION
Thanh D. Hoang, DO, FACP, FACE Division of Endocrinology Department of Internal Medicine WRNMMC 13 Aug 2018 OVERVIEW OF PRESENTATION Take Home Points Definition of Hypogonadism Clinical Manifestations
More informationR. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga and Tobias S. K ohler
Sexual Function/Infertility Validity of Midday Total Testosterone Levels in Older Men with Erectile Dysfunction R. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga
More informationDiagnosis and management of sexual dysfunction. Dr Chris Simpson Consultant Psychiatrist
Diagnosis and management of sexual dysfunction Dr Chris Simpson Consultant Psychiatrist What are we talking about? Male Erectile dysfunction Premature ejaculation Delayed ejaculation Sexual aversion Paraphilia
More informationConsent for Testosterone Therapy-Men Revised 4/10/18
Consent for Testosterone Therapy in Men You have been diagnosed with or have an increased risk of having a hormone deficiency and your provider has recommended treatment with bio-identical hormone replacement
More informationFAILURE IS NOT AN OPTION HOPE IS NOT A PLAN
FAILURE IS NOT AN OPTION HOPE IS NOT A PLAN Doctors' Secrets What Men Want - Testosterone - Sharing the Secrets of Men s Health Donald M. McLeod M.D. and Philip A White M.D. CONTENTS SECTION I Introduction
More informationAndrogens. Medication Strengths Quantity Limit Comments Androderm (testosterone patch) 1% pump 2 pump bottles per Non-Preferred
Market DC Androgens Override(s) Prior Authorization Quantity Limit Approval Duration Varies upon diagnosis Medication Strengths Quantity Limit Comments Androderm (testosterone patch) AndroGel (testosterone
More informationWhat Is the Low T Syndrome? Is Testosterone Supplementation Safe?
What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or
More informationMale Hypogonadism. Types and causes of hypogonadism. What is male hypogonadism? Symptoms. Testosterone production. Patient Information.
Patient Information English 31 Male Hypogonadism The underlined terms are listed in the glossary. What is male hypogonadism? Male hypogonadism means the testicles do not produce enough of the male sex
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel AXIRON transdermal solution FORTESTA transdermal gel NATESTO nasal gel STRIANT buccal mucoadhesive
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.37 Subject: Testosterone Powder Page: 1 of 12 Last Review Date: November 30, 2018 Testosterone powder
More informationLate Onset Hypogonadism. Toh Charng Chee Hospital Selayang
Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of
More informationHormone Replacement Therapy
Hormone Replacement Therapy What Role Should It Play With Our Patients? Noel R. Williams MD, FACOG TESTOSTERONE FOR MEN: SALVATION OR SNAKE OIL? Definition Male hypogonadism means the testicles don't produce
More informationUpdate on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D.
The General Practice Education Day Healthed / Generation Next August 22 nd Sydney Update on Androgen Deficiency Robert I. McLachlan, FRACP, PhD Director, Andrology Australia Principal Research Fellow,
More informationBalancing Hormone Function in Women By Meghna Thacker, NMD
Balancing Hormone Function in Women By Meghna Thacker, NMD Hormone function is central to health and well being in both men as well as women. A problem encountered with any one endocrine gland can lead
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: June 24, 2016 Testosterone Oral Buccal Nasal Description
More informationTestosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands
Testosterone Therapy and the Prostate Frans M.J. Debruyne Professor of Urology The Netherlands TRT- Risks Prostate ( Cancer, BPH )? Cardiac? Lipids? Polycythemia Sleep apnea Gynecomastia Edema Testosterone
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationMALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY. Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism
MALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism Disclosures Aromatase inhibitors & clomiphene citrate are
More informationTherapeutic Cohort Results
Patient: JANE DOE DOB: December 31, 1968 Sex: F MRN: Order Number: Completed: February 26, 2016 Received: February 26, 2016 Collected: February 26, 2016 One Day Hormone Check - Salivary Profile Therapeutic
More informationSexual Dysfunction. Jae Il Kang, Byeong Kuk Ham, Mi Mi Oh, Je Jong Kim, Du Geon Moon. DOI: /kju
www.kjurology.org DOI:10.4111/kju.2011.52.6.416 Sexual Dysfunction Correlation between Serum Total Testosterone and the AMS and IIEF Questionnaires in Patients with Erectile Dysfunction with Testosterone
More informationMale Patient Questionnaire & History
Male Patient Questionnaire & History Name: Today s Date: (Last) (First) (Middle) Date of Birth: Age: Weight: Occupation: Home Address: City: State: Zip: E-Mail Address: May we contact you via E-Mail? (
More informationTestosterone Replacement in Adults. John A. Seibel, MD, FACP, MACE
Testosterone Replacement in Adults John A. Seibel, MD, FACP, MACE Disclosures None! *Privately Authenticated Definition of Male Hypogonadism inadequate gonadal function, as manifested by deficiencies in
More informationTherapeutic Cohort Results
Patient: SAMPLE PATIENT DOB: Sex: MRN: Menopause Plus - Salivary Profile Therapeutic Cohort Results Hormone Average Result QUINTILE DISTRIBUTION 1st 2nd 3rd 4th 5th Therapeutic Range* Estradiol (E2) 8.7
More informationAromatase Inhibitors in Male Infertility:
Aromatase Inhibitors in Male Infertility: The hype of hypogonadism? BEATRIZ UGALDE, PHARM.D. H-E-B/UNIVERSITY OF TEXAS COMMUNITY PHARMACY PGY1 03 NOVEMBER 2017 PHARMACOTHERAPY ROUNDS Disclosures No conflicts
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationHIGHLIGHTS. From Testosterone Update Disease State Theater. American Urological Association and Endocrine Society Annual Meetings
HIGHLIGHTS From Testosterone Update Disease State Theater Presentations held at the 2008 American Urological Association and Endocrine Society Annual Meetings Jointly sponsored by the Annenberg Center
More informationHuman Physiology 6.6- Hormones, Homeostasis, and Reproduction
Human Physiology 6.6- Hormones, Homeostasis, and Reproduction Essential idea: Hormones are used when signals need to be widely distributed. Application: William Harvey s investigation of sexual reproduction
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.37 Subject: Testosterone Powder Page: 1 of 11 Last Review Date: September 18, 2015 Testosterone powder
More informationTestosterone Therapy in Adult Men with Androgen Deficiency Syndromes:
The Endocrine Society s CLINICAL GUIDELINES Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline Authors: Shalender Bhasin, Glenn R. Cunningham,
More informationTUE Application for Testosterone Physician Worksheet
TUE Application for Testosterone Physician Worksheet Attention Physicians - USADA will not process Therapeutic Use Exemptions (TUE) for the use of testosterone unless all of the requirements for documentation
More informationTestim 1 Gel: Review of Clinical Data
European Urology Supplements European Urology Supplements 4 (2005) 24 30 Testim 1 Gel: Review of Clinical Data Tom A. McNicholas* Department of Urology, Lister Hospital, Corey s Mill Lane, Stevenage, Hertfordshire
More informationHormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index
Hormonal Health PATIENT: Sample Report TEST REF: TST-12345 Hormonal Health 0.61 0.30-1.13 ng/ml DHEA-S 91 35-430 mcg/dl tient: SAMPLE TIENT e: x: N: Sex Binding Globulin 80 18-114 nmol/l Testosterone 0.34
More informationGP guide to testosterone replacement therapy in men
GP guide to testosterone replacement therapy in men SPL Mike Kirby FRCP Professor Mike Kirby describes how the diagnosis and treatment of test - osterone deficiency in primary care can lead to improved
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationThe Centre for Men s Health
96 Harley Street (London) and Manchester All Enquiries - +44 (0)20 7486 2277 www.centreformenshealth.co.uk/ This leaflet provides information about: The Centre for Men s Health The conditions we treat:
More informationOne Day Hormone Check
One Day Hormone Check Patient: EMILY TEST DOB: January 18, 1948 Sex: F MRN: 0000000004 Order Number: J5070009 Completed: March 07, 2014 Received: March 07, 2014 Collected: March 07, 2014 Alec Smart, ND
More informationPrior Authorization Criteria Update: Androgens, Topical and Parenteral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationX/99/$03.00/0 Vol. 84, No. 10 The Journal of Clinical Endocrinology & Metabolism Copyright 1999 by The Endocrine Society
0021-972X/99/$03.00/0 Vol. 84, No. 10 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society Pharmacokinetics, Efficacy, and Safety of a Permeation-
More informationEPILEPSY. & Men s Health
EPILEPSY & Men s Health HORMONAL EFFECTS in Men with Epilepsy Does epilepsy affect hormones? Yes, epilepsy is associated with hormonal changes. For instance, experts estimate that approximately 40 percent
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationMale Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products.
Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. 3-30-2015; web William E. Winter, MD University of Florida Departments of Pathology
More informationProf. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany
Induction of fertility in hypogonadal men Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany Induction of fertility in hypogonadal men Prof.
More informationMale Reproductive System
Male Hormone Issues The Ideal Male What describes a healthy male? Happy guy, well-muscled, good sex drive, focused brain This is what a guy can expect with the right level of testosterone Low testosterone?
More informationtestosterone and LH concentrations in the morning ( hours) and evening ( hours).
Original Article SERUM TESTOSTERONE AND LH IN HEALTHY MEN BOYCE et al. Are published normal ranges of serum testosterone too high? Results of a cross-sectional survey of serum testosterone and luteinizing
More informationMen Getting Older Will Testosterone Keep Him Young?
Men Getting Older Will Testosterone Keep Him Young? Alvin M. Matsumoto, M.D. Associate Director, GRECC V.A. Puget Sound Health Care System Professor, Department of Medicine Division of Gerontology and
More informationTestosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline
CLINICAL PRACTICE GUIDELINE Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline Shalender Bhasin, 1 Juan P. Brito, 2 Glenn R. Cunningham, 3 Frances J. Hayes,
More information